Lumbar puncture

PreclinicalBiologic

Takeda

Lumbar puncture is one of 87 biologic programs targeting Frontotemporal Dementia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

MemoryActive, not recruiting

Alzheimer DiseaseRecruiting

Frontotemporal DementiaPreclinical

Active, not recruiting

MemoryPreclinical

Active, not recruiting

Alzheimer DiseasePreclinical

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Lexapro

Calciferol

Azilect

Neupro

Evista

Niacor

Epidiolex

Celebrex

PPhiladelphia Eye Associates

Approved

1 9

Kisunla

Eli Lilly

Phase 3

4 10

Transderm Scop

BBaxter Healthcare Corporation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Frontotemporal Dementia

NCT05288842

Q4 2030

PreclinicalRecruiting

Alzheimer Disease

NCT05806697

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Completed· Takeda logo

Takeda·Phase 1·NCT01387594·49 enrolled

Vitamin D31 trial

Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome

Completed·—·Phase 3·NCT01817166·316 enrolled

Frontotemporal Dementia1 trial

Tanycytes in Alzheimer's Disease and Frontotemporal Dementia

Recruiting·UUniversity Hospital, Lille··NCT05288842·102 enrolled

Monotherapy1 trial

Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT01116817·35 enrolled

Alzheimer disease1 trial

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study

Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Preclinical·NCT05806697·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Lumbar puncture. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lumbar puncture compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lumbar puncture. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Takeda

Lumbar puncture

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2030

Trials by Indication[1]

Ulcerative Colitis1 trial

Vitamin D31 trial

Frontotemporal Dementia1 trial

Monotherapy1 trial

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News